Ivosidenib, an orally available small-molecule inhibitor targeting mutant IDH1, received FDA approval in August 2021 for the treatment of IDH1-mutant CCA that is refractory to chemotherapy. The gene discussed is IDH1; the disease is cholangiocarcinoma.